Tanzania - English - Tanzania Medicinces & Medical Devices Authority

sri balaji pharma limited, tanzania - benzoic acid , salicylic acid - solution - benzoic acid 6%w/v salicylic acid 3% solution %w/v

Namibia - English - Namibia Medicines Regulatory Council

resmed pharmaceuticals - benzoic acid, salicylic acid - ointment - each 100g contains benzoic acid 6g and salicylic acid 3g

United States - English - NLM (National Library of Medicine)

trinity pharmaceuticals, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - for dermatologic use: salicylic acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). for podiatric use: salicylic acid 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. salicylic acid 6% should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. salicylic acid 6% should not be used in children under 2 years of age.

United States - English - NLM (National Library of Medicine)

trinity pharmaceuticals, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - for dermatologic use: salicylic acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). for podiatric use: salicylic acid 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. salicylic acid 6% should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. salicylic acid 6% should not be used in children under 2 years of age.

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - indications and usage for dermatologic use: salicylic acid 6% foam is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris and psoriasis. for podiatric use: salicylic acid 6% foam is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. contraindications salicylic acid 6% foam should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. salicylic acid 6% foam should not be used in children under 2 years of age.

United States - English - NLM (National Library of Medicine)

jacobus pharmaceutical company, inc. - aminosalicylic acid (unii: 5b2658e0n2) (aminosalicylic acid - unii:5b2658e0n2) - aminosalicylic acid 4 g - paser is indicated for the treatment of tuberculosis in combination with other active agents. it is most commonly used in patients with multi-drug resistant tb (mdr-tb) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. when paser is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible. hypersensitivity to any component of this medication. severe renal disease. patients with severe renal disease will accumulate aminosalicylic acid and its acetyl metabolite but will continue to acetylate, thus leading exclusively to the inactive acetylated form; deacetylation, if any, is not significant. the half life of free aminosalicylic acid in renal disease is 30.8 minutes in comparison to 26.4 minutes in normal volunteers. but the half life of the inactive metabolite is 30

United States - English - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim) - benzoic acid 1 [hp_x] - gout, tendonitis condition listed above or as directed by the physician

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - benzoic acid; salicylic acid - cutaneous cream - 60mg/1gram ; 30mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - benzoic acid; salicylic acid - cutaneous ointment - 60mg/1gram ; 30mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - benzoic acid; salicylic acid - cutaneous ointment - 60mg/1gram ; 30mg/1gram